---

---

SECURITIES AND EXCHANGE COMMISSIONWASHINGTON, DC 20549

---

FORM 10-KSB

ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934

For the fiscal year endedSeptember 30, 2001

Commission file number1-9431

---

ESCAGENETICS CORPORATION(Name of Small Business Issuer in Its Charter)

|Delaware(State or Other Jurisdiction of
Incorporation or Organization)                |  | 94-3012230(I.R.S. Employer
Identification No.)
|------------------------------------------------------------------------------------- |  | ----------------------------------------------
|                                                                                      |  |                                               
|Suite 605, 1075 Bellevue Way NE, Bellevue, WA(Address of Principal Executive Offices) |  | 98004(Zip Code)                               

(206) 901-3595(Issuer's Telephone Number, Including Area Code)

Securities
registered under Section 12(b) of the Exchange Act: None

Securities registered under Section 12(g) of the Exchange Act: Common Stock, $0.0001 par value per share.

---

Check whether the issuer: (1) filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act during the past 12 months
(or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for past
90 days. Yes /x/  No / /

Check
if disclosure of delinquent filers in response to Item 405 of Regulation S-B is not contained in this form, and no disclosure will be contained, to the best
of registrant's knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-KSB or any amendment to this
Form 10-KSB. / /

Issuer's
revenues for its most recent fiscal year were $-0-.

As
of October 22, 2001, the aggregate market value of the voting stock held by non-affiliates (based upon the average bid and asked price on such date) was $73,425.

Check
whether the issuer has filed all documents and reports required to be filed by Section 12, 13, or 15(d) of the Exchange Act after the distribution of securities under a
plan confirmed by a court. Yes /x/  No / /

The
number of shares outstanding of the issuer's common stock as of October 31, 2001 was 73,402,516 shares.

Transitional
Small Business Disclosure Format (check one): Yes / /  No /x/

---

---

---

Part I

Item 1Description of Business

Formed
in 1986, ESCAgenetics Corporation ("the Company") was organized to develop and commercialize high-value, plant derived products for the agricultural and
pharmaceutical markets. The Company actively conducted its business between 1987 and the early part of 1995. In January 1995, the Company scaled back its business activities and became largely
a dormant business. In January 1996, the Company filed a bankruptcy petition for protection under Chapter 11 of the U.S. Bankruptcy Code.

The
Company's amended plan of reorganization (the "Amended Plan of Reorganization") became effective on August 22, 1996. Under the Amended Plan of Reorganization, GFL Ultra
Fund, Ltd. ("Ultra"), the Company's largest debt holder, received 25% of the cash available to unsecured creditors and 90% of the Company's common stock. The remaining cash was distributed
proportionately to the remaining unsecured creditors and the remaining 10% of the Company's common stock remained owned by its previous shareholders. The bankruptcy proceeding was officially closed
effective March 31, 1997. In July, 1998 Genesee Holdings, Inc. ("Holdings") acquired by merger all the assets of Ultra.

By
the end of 1996, the Company sold or disposed of all of its assets other than cash on hand and the stock of PHYTOpharmaceuticals, Inc. (an inactive majority owned
subsidiary) and SRE ESCAgenetics Corporation (an inactive wholly owned subsidiary).

The
Company has been dormant during the fiscal year ended September 30, 2001. The Company has had no employees since November 1996. The Company does not plan to continue
the business activities that it conducted prior to its reorganization. It plans to pursue a business combination or other strategic transaction. No candidate for such a transaction has been
identified. The Company believes its status as a public company may be attractive to a private company wishing to avoid an initial public offering but there is no guarantee that a business combination
or other strategic transaction will be consummated.

Item 2Description of Property

None.

Item 3Legal Proceedings

None.

Item 4Submission of Matters to a Vote of Security Holders

No
matters were submitted to a vote of the shareholders during the fourth quarter of fiscal 2001.

---

Part II

Item 5Market for Common Equity and Related Shareholder Matters

The
Company's Common Stock trades under the symbol "ESNG" on the OTC Bulletin Board. The market for the Company's Common Stock is limited, sporadic and highly volatile. The following
table sets forth the high and low bid prices per share of the Company's Common Stock during its last two fiscal years as reported by the OTC Bulletin Board. These prices reflect inter-dealer prices,
without retail mark-ups, mark-downs or commissions, and may not necessarily represent actual transactions.

|            |                | High |        | Low
|----------- | -------------- | ---- | ------ | ---
|Fiscal 2000 |                |      |        |    
|            | First Quarter  |      | 0.1300 |    
|            | Second Quarter |      | 0.2000 |    
|            | Third Quarter  |      | 0.1100 |    
|            | Fourth Quarter |      | 0.0550 |    
|Fiscal 2001 |                |      |        |    
|            | First Quarter  |      | 0.0313 |    
|            | Second Quarter |      | 0.0290 |    
|            | Third Quarter  |      | 0.0220 |    
|            | Fourth Quarter |      | 0.0150 |    

The
number of shareholders of record as of September 30, 2001 was 489.

It
is the present policy of the Company not to pay cash dividends. Any payment of cash dividends in the future will depend upon the amount of funds legally available for that purpose,
the Company's earnings, financial condition, capital requirements and other factors that the Board of Directors may deem relevant.

Item 6Management's Discussion and Analysis or Plan of Operation

The
Company has had no revenues from operations since the reorganization date. The Company does not plan to continue the business activities that it previously conducted. It plans to
pursue a business combination or other strategic transaction. No candidate for such a transaction has been identified. The Company believes its status as a public company may be attractive to a
private company wishing to avoid an initial public offering but there is no guarantee that a business combination or other strategic transaction will be consummated.

The
Company expects to fund its expenses during fiscal 2002 with advances from its majority shareholder, Holdings. These advances are expected to total approximately $50,000 during
fiscal 2002. The Company expects Holdings to continue to fund its expenses until a business combination or other strategic transaction is consummated. There is no guarantee that the Company is a
viable party for a business combination or other strategic transaction. If a business combination or other strategic transaction is not consummated in a timeframe suitable to Holdings or cannot be
consummated due to excessive cost or for any other reason, Holdings may cease to advance funds to the Company.

The
Company has no employees and no fixed assets. The Company does not anticipate hiring any employees or purchasing any assets until such time as a business combination or other
strategic transaction is consummated or is imminent.

Item 7Financial Statements

The
financial statements of the Company are included in this report commencing on page F-1.

Item 8Changes In and Disagreements with Accountants on Accounting and Financial Disclosure

None.

---

Part III

Item 9Directors, Executive Officers, Promoters and Control Persons; Compliance with Section 16(a) of the  Exchange Act

Executive Officers and Directors

The following table sets forth the name, age and position of each person who was serving as an executive officer or director of the Company as of
November 1, 2001:

Name

Age

OfficeMichelle Kline

43

President, Treasurer, Secretary, DirectorGreg L. Key

36

Director


Ms. Kline
was appointed as an officer and director on August 23, 1996. Mr. Key was appointed as a director on October 9, 1998. Ms. Kline and
Mr. Key have been employees of Genesee Services Corp., an affiliate of Holdings, since 1990.

Section 16(a) Beneficial Ownership Reporting Compliance

Section 16(a) of the Securities Exchange Act of 1934, as amended, requires the Company's officers and directors, and persons who own more than ten
percent of a registered class of the Company's equity securities, to file reports of ownership and changes of ownership with the Securities and Exchange
Commission (the "SEC"). Officers, directors and greater than ten percent shareholders are required by SEC regulation to furnish the Company with copies of all such reports they file.

Based
solely on its review of the copies of such reports received by the Company, the Company believes that, during the fiscal year ended September 30, 2001, all filing
requirements applicable to its officers and directors, and all of the persons known to the Company to own more than ten percent of its Common Stock, were complied with by such persons.

Item 10Executive Compensation

The
Company has had no employees since November 1996 and did not compensate its officer or directors during the fiscal year ended September 30, 2001. Ms. Kline
and Mr. Key are compensated by their employer for services rendered to their employer. No portion of their compensation is specifically attributable to their service as an officer or director
of the Company.

Item 11Security Ownership of Beneficial Owners and Management

The
table below sets forth information as to the beneficial owner of record that was known by the Company to own beneficially more than 5% of the issued and outstanding Common Stock
of the Company as of October 10, 2001.

|Title of Class |  | Name and Address of
Beneficial Owner                                                                   |  | Amount and Nature of
Beneficial Ownership |  | Percent of
Class
|-------------- |  | ------------------------------------------------------------------------------------------------------ |  | ----------------------------------------- |  | ----------------
|Common Stock   |  | Genesee Holdings, Inc.
c/o ESCAgenetics Corporation
Suite 605, 1075 Bellevue Way NE
Bellevue, WA 98004 |  | 93,230,000 shares*                        |  | 92.7%           

---

Neither
Ms. Kline nor Mr. Key beneficially owns any shares of the Company or an interest in Holdings.

---

Item 12Certain Relationships and Related Transactions

At
September 30, 2001 the Company owed $209,000 to Holdings for loans provided to finance the Company's business activities. The loans are convertible into equity at the rate
of 130 shares per dollar at Holding's option. Holdings has waived its right to receive interest on the loans through September 30, 2001.

During
the fiscal year ended September 30, 2001, the Company paid $4,930 to an affiliate of Holdings for general and administrative expenses consisting primarily of accounting
and research services.

Item 13Exhibits, Lists and Reports on Form 8-K

(a)  The
following exhibits are filed as part of this report:

Exhibit #



Exhibit Title3.1

*

Certificate of incorporation3.2

**

By-laws21



Subsidiaries of registrant


---

---



SIGNATURES

In accordance with Section 13 or 15(d) of the Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned, thereunto
duly authorized.

|ESCAGENETICS CORPORATION |  |                                          
|------------------------ |  | -----------------------------------------
|                         |  |                                          
|                         |  |                                          
|By                       |  | /s/MICHELLE KLINEMichelle Kline,President
|                         |  |                                          
|Dated: November 1, 2001  |  |                                          

In
accordance with the Exchange Act, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.

|/s/MICHELLE KLINEMichelle Kline,Principal Executive, Financial
and Accounting Officer and Director |  | 
|-------------------------------------------------------------------------------------------------- |  | 
|                                                                                                   |  | 
|Date: November 1, 2001                                                                             |  | 
|                                                                                                   |  | 
|                                                                                                   |  | 
|/s/GREG L. KEYGreg L. Key,Director                                                                 |  | 
|                                                                                                   |  | 
|Date: November 1, 2001                                                                             |  | 

---



Independent Auditors' Report

Board
of Directors and Shareholders
ESCAgenetics Corporation and Subsidiaries
Bellevue, Washington

We
have audited the accompanying consolidated balance sheet of ESCAgenetics Corporation and Subsidiaries (the Company) as of September 30, 2001, and the related consolidated
statements of operations and cash flows for the years ended September 30, 2001 and 2000. These financial statements are the responsibility of the Company's management. Our responsibility is to
express an opinion on these financial statements based on our audits.

We
conducted our audits in accordance with auditing standards generally accepted in the United States of America. Those standards require that we plan and perform the audit to obtain
reasonable assurance about whether the financial statements are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the
financial statements. An audit also includes assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation.
We believe that our audits provide a reasonable basis for our opinion.

In
our opinion, the financial statements referred to above present fairly, in all material respects, the financial position of ESCAgenetics Corporation and Subsidiaries as of
September 30, 2001, and the results of their operations and their cash flows for the years ended September 30, 2001 and 2000, in conformity with auditing standards generally accepted in
the United States of America.

The
accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 1 to the financial statements, the
Company has not established profitable operations, which raises substantial doubt about its ability to continue as a going concern.
Management's plans in regard to these matters are also described in Note 1. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

BADER
MARTIN ROSS & SMITH, P.S.
Seattle, Washington

November 1,
2001

F1

---



ESCAGENETICS CORPORATION AND SUBSIDIARIES        CONSOLIDATED BALANCE SHEET        SEPTEMBER 30, 2001

|ASSETS                                          |                               |                                       |                                                       |         
|----------------------------------------------- | ----------------------------- | ------------------------------------- | ----------------------------------------------------- | --------
|Current assetscash                             |                               | $                                     | 11,000                                                |         
|                                                |                               |                                       |                                                      
|                                                |                               | Total assets                          |                                                       | $       
|                                                |                               |                                       |                                                      
|LIABILITIES AND SHAREHOLDERS' EQUITY DEFICIENCY |                               |                                       |                                                       |         
|Liabilities:                                    |                               |                                       |                                                       |         
|                                                | Accounts payable              |                                       | $                                                     | 6,000   
|                                                | Due to Genesee Holdings, Inc. |                                       |                                                       | 209,000 
|                                                |                               |                                       |                                                      
|                                                |                               | Total liabilities, all current        |                                                       |         
|                                                |                               |                                       |                                                      
|Shareholders' equity deficiency:                |                               |                                       |                                                       |         
|                                                | Common stock                  |                                       |                                                       | 7,000   
|                                                | Additional paid-in capital    |                                       |                                                       | 134,000 
|                                                | Accumulated deficit           |                                       |                                                       | (345,000
|                                                |                               |                                       |                                                      
|                                                |                               | Total shareholders' equity deficiency |                                                       |         
|                                                |                               |                                       |                                                      
|                                                |                               |                                       | Total liabilities and shareholders' equity deficiency |         
|                                                |                               |                                       |                                                      

See notes to consolidated financial statements.

F2

---



ESCAGENETICS CORPORATION AND SUBSIDIARIES        CONSOLIDATED STATEMENTS OF OPERATIONS

|                                           |                            | Years ended September 30, |           
|------------------------------------------ | -------------------------- | ------------------------- | ----------
|
|Revenues                                   |                            | $                         | 0         
|                                           |                            |                           |           
|Operating expenses:                        |                            |                           |           
|                                           | Accounting and legal       |                           |           
|                                           | General and administrative |                           |           
|                                           |                            |                           |           
|                                           |                            | Total expenses            |           
|                                           |                            |                           |           
|Net loss                                   |                            |                           | (38,000   
|Accumulated deficit, beginning of year     |                            |                           | (307,000  
|                                           |                            |                           |           
|Accumulated deficit, end of year           |                            | $                         | (345,000  
|                                           |                            |                           |           
|Net loss per share                         |                            | $                         | (0.00     
|                                           |                            |                           |           
|Weighted average common shares outstanding |                            |                           | 73,402,516
|                                           |                            |                           |           

See notes to consolidated financial statements.

F3

---



ESCAGENETICS CORPORATION AND SUBSIDIARIES        CONSOLIDATED STATEMENTS OF CASH FLOWS

|                                                                                |                            | Years ended September 30,             |       
|------------------------------------------------------------------------------- | -------------------------- | ------------------------------------- | ------
|
|Cash flows from operating activities:                                           |                            |                                       |       
|                                                                                | Net loss                   |                                       | $     
|                                                                                | Change in accounts payable |                                       |       
|                                                                                |                            |                                       |       
|                                                                                |                            | Net cash used in operating activities |       
|                                                                                |                            |                                       |       
|Net cash provided by financing activities, advances from Genesee Holdings, Inc. |                            |                                       | 49,000
|                                                                                |                            |                                       |       
|Net increase (decrease) in cash                                                 |                            |                                       | 10,000
|Cash at beginning of year                                                       |                            |                                       | 1,000 
|                                                                                |                            |                                       |       
|Cash at end of year                                                             |                            | $                                     | 11,000
|                                                                                |                            |                                       |       

See notes to consolidated financial statements.

F4

---



ESCAGENETICS CORPORATION AND SUBSIDIARIES        NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

1.  Summary of significant accounting policies



The consolidated financial statements include the accounts of ESCAgenetics Corporation (the "Company") and its majority and wholly owned subsidiaries,
PHYTOpharmaceuticals, Inc. and SRE ESCAgenetics Corporation, after elimination of all significant intercompany accounts and transactions. The Company's subsidiaries did not have any significant
operating activities during the periods presented.



Formed in 1986, the Company was organized to develop and commercialize high-value, plant-derived products for the agricultural and pharmaceutical
markets. In January 1995, the Company scaled back its
business activities and became largely a dormant business. In January 1996, the Company filed a bankruptcy petition for protection under Chapter 11 of the U.S. Bankruptcy Code, and the
Company's plan of reorganization became effective on August 22, 1996. The bankruptcy proceeding was officially closed effective March 31, 1997.

Genesee
Holdings, Inc. ("Holdings") owns ninety percent of the outstanding common stock of the Company. Currently, all operating expenses are being funded by Holdings through a
line of credit (Note 3). During the years ended September 30, 2001 and 2000, the Company paid $4,930 and $6,090, respectively, to an affiliate for operating expenses.

The
Company does not plan to continue the business activities that it conducted prior to its reorganization. It plans to pursue a business combination or other strategic transaction.
No candidate for such a transaction has been identified. Ultimately, the continuation of the Company as a going concern is dependent upon the establishment of profitable operations. Management
believes Holdings will continue to fund expenditures until such time as a business combination or other strategic transaction is consummated.

Because
the achievement of these plans is dependent upon future events, there can be no assurance that future profitable operations will occur as planned.



The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make
estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from those estimates.



Net loss per share is calculated on the basis of weighted average number of common shares outstanding. Common stock equivalents are excluded from the
computation, as their effect is antidilutive.

2.  Shareholders' equity

The Company has authorized 101,000,000 shares of Common Stock with a par value of $.0001 per share and 1,000,000 shares of Preferred Stock with a par value of
$.01 per share. There were 73,402,516

F5

---

shares of Common Stock issued and outstanding at September 30, 2001 and 2000. No shares of Preferred Stock are outstanding.

3.  Due to Holdings

At September 30, 2001, the Company owed $209,000 to Holdings for advances provided to finance the Company's expenses. The advances are convertible into
equity at the rate of 130 shares per dollar at Holdings' option. Holdings has waived its right to receive interest on the loans through September 30, 2001.

4.  Income taxes

The Company has accumulated net operating loss carryforwards of approximately $210,000 that are available to offset future taxable income, if any, through
2020. Realization of the net operating loss carryforwards is dependent upon future profitable operations. Accordingly, management has recorded a valuation allowance to reduce deferred tax assets
associated with net operating loss carryforwards to zero at September 30, 2001.

F6

---

QuickLinks